Med Ed Report briefs: November 2013

Share this article:
Jackie Richards
Jackie Richards

Multimedia education firm Oakstone Publishing hired Amy Skiff as VP marketing. Skiff, formerly VP marketing at B.A.S.S., will be responsible for all aspects of strategic development and execution of marketing plans for Oakstone's medical and wellness divisions.

Informatics and e-learning outfit ArcheMedx, together with partners Prova, ReachMD, AcademicCME and Elsevier, launched a series of case-based and video-based lessons powered by its ­ArcheViewer self-directed learning environment.

NJ physician-owned malpractice coverage provider Conventus is offering, at no cost to its members, an online CME program featuring over 50 clinically-based CME courses.

Jackie Richards was promoted to VP, client services, at CircleScience, a division of KnowledgePoint360 Group. She joined in 2012, from Gardiner-Caldwell Communications.

Surgical products company AxoGen sponsored two educational forums at the American Society for Surgery of the Hand (ASSH) 2013 Annual Meeting, both aimed at improving outcomes for peripheral nerve repair.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?